Zacks Investment Research Upgrades Aytu Bioscience (AYTU) to Buy

Zacks Investment Research upgraded shares of Aytu Bioscience (NASDAQ:AYTU) from a hold rating to a buy rating in a research note issued to investors on Monday morning. Zacks Investment Research currently has $1.50 price objective on the stock.

According to Zacks, “Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company’s marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. “

AYTU opened at $1.60 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.37 and a current ratio of 4.72. Aytu Bioscience has a 1 year low of $0.68 and a 1 year high of $15.20. The company has a market capitalization of $19.80 million, a P/E ratio of -0.06 and a beta of 4.98.

Aytu Bioscience (NASDAQ:AYTU) last released its earnings results on Thursday, February 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.37). Aytu Bioscience had a negative return on equity of 95.53% and a negative net margin of 217.45%. The company had revenue of $1.80 million during the quarter, compared to analyst estimates of $1.58 million. As a group, equities research analysts anticipate that Aytu Bioscience will post -2.39 EPS for the current year.

An institutional investor recently bought a new position in Aytu Bioscience stock. Wexford Capital LP bought a new position in Aytu Bioscience Inc (NASDAQ:AYTU) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 89,500 shares of the company’s stock, valued at approximately $71,000. Wexford Capital LP owned about 1.04% of Aytu Bioscience as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 29.94% of the company’s stock.

Aytu Bioscience Company Profile

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Further Reading: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on Aytu Bioscience (AYTU)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit